Digest Réseau Comment ça marche
Réseau
/
Sociétés
Bo
Non vérifié

Boehringer Ingelheim Limited

Ce que nous écrivons

Annonces ÉconomiquesIndustrie pharmaceutiqueManagement/Organisation d'EntrepriseMédecine Santé Bien-êtrePublicité/Marketing/Médias/Communication

47 communiqués de presse

Voir tous les communiqués de presse
29/04/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer Ingelheim and Eko Health Inc. launch new AI-based solution that detects heart murmurs in dogs
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
27/04/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
20/04/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK’s Knowledge Quarter
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
15/04/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
13/04/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
09/04/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
09/04/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
24/03/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
26/02/2026
Industrie pharmaceutique
Médecine Santé Bien-être
FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0
26/02/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics
Source
Boehringer Ingelheim Limited
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0